JNJ's 23x forward P/E for double-digit oncology growth undercuts KO's 26x multiple, making JNJ the stronger risk-reward defensive anchor right now.
KO's 12% revenue surge masks thin fundamentals, given that only 3% volume growth means most gains came from pricing that could reverse.
Polymarket traders price a 92% chance JNJ beats its next earnings, fueled by DARZALEX and TREMFYA absorbing STELARA's biosimilar erosion.
This lithium producer surpassed a $1B private valuation, joining some of America's most powerful startups. Now you can invest in EnergyX alongside global giants like General Motors, but only through July 16. (sponsor)
Johnson & Johnson (NYSE:JNJ) and Coca-Cola (NYSE:KO) both delivered Q1 2026 beats and both are being crowded into by capital rotating out of tech. JNJ has broken out past $259, while KO just tagged an all-time high near $84.14. That backdrop makes this a real premium-defensive showdown.
KO's 12% revenue surge masks thin fundamentals, given that only 3% volume growth means most gains came from pricing that could reverse.
Polymarket traders price a 92% chance JNJ beats its next earnings, fueled by DARZALEX and TREMFYA absorbing STELARA's biosimilar erosion.
This lithium producer surpassed a $1B private valuation, joining some of America's most powerful startups. Now you can invest in EnergyX alongside global giants like General Motors, but only through July 16. (sponsor)
Johnson & Johnson (NYSE:JNJ) and Coca-Cola (NYSE:KO) both delivered Q1 2026 beats and both are being crowded into by capital rotating out of tech. JNJ has broken out past $259, while KO just tagged an all-time high near $84.14. That backdrop makes this a real premium-defensive showdown.
3 months ago
